Zai Lab reports Q1 EPS (4c), consensus (53c)

Reports Q1 revenue $99.6M, consensus $108.43M. “We continue to accelerate the development of our global pipeline, with numerous clinical trials underway across oncology and immunology,” said CEO Samantha Du. “During the quarter, we made strong progress advancing zoci, with AACR data reinforcing its differentiated profile in both SCLC and epNECs, collaborations with Amgen and Boehringer Ingelheim to evaluate zoci as a potential backbone therapy, and rapid enrollment in the registrational DLLEVATE study…We also continue to advance our growing portfolio of global clinical programs, including ZL-1503 for atopic dermatitis…At the same time, our commercially profitable regional business provides a stable foundation, with several near-term opportunities expected to support future growth.” “We are deepening our presence in key markets to capitalize on underlying demand for VYVGART and are expanding our regional footprint as we prepare for the launch of KarXT in China in Q2,” said COO Josh Smiley. “KarXT’s launch positions us to bring the first novel therapy in decades to this critical market, with potential NRDL inclusion next year. In addition, we anticipate a potential regulatory approval for TIVDAK this year, and with positive Phase 3 readouts for povetacicept and elegrobart, we have additional opportunities for future growth.”